Relmada Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-6.3M | $-3.0M | $-20.8M | $-19.9M | $-6.9M |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | $85.3K | $54.8K | $9.3K | $373 | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $704.5K | $1.0M | $797.0K | $382.3K | $37.3K |
| Net Cash from Operating Activities | $-6.5M | $-13.1M | $-16.2M | $-2.2M | $-1.6M |
| Investing Activities | |||||
| Capital Expenditures | $49.7K | $562.3K | $23.3K | $8.9K | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-49.7K | $-562.3K | $-23.3K | $-8.9K | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $-273.7K | $-263.8K | $13.2M | $4.0M | $3.3M |
| Net Change in Cash | $-6.8M | $-14.0M | $-3.1M | — | — |
| Free Cash Flow | $-6.5M | $-13.7M | $-16.3M | $-2.2M | — |